SOURCE: Equity News Circuit

Equity News Circuit

April 25, 2013 08:20 ET

Free Research Reports on BCS, PG, SVU and TMO Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - Apr 25, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Barclays PLC (NYSE: BCS) shares declined approximately 1.4 percent Wednesday after reporting results for the first quarter of 2013. The company reported an adjusted profit after tax 839 million pounds ($1.3 billion) for the first quarter, compared to a loss of 589 million pounds a year ago.

Find out more about Barclays including full access to the free equity report at:

The Procter & Gamble Company (NYSE: PG) shares declined approximately 4.6 percent on more than double the average daily volume Wednesday. The consumer product manufacturer in their recent earnings release stated that they expect full year net income of $3.96 to $4.04 per share, which fell short of analysts' expectations of $4.37 per share.

Find out more about Procter & Gamble including full access to the free equity report at:

Supervalu Inc. (NYSE: SVU) shares spiked over 6 percent on double the average daily volume Wednesday. The company reported revenues of $3.89 billion for the fiscal first quarter, a decrease of 2 percent when compared to a year ago. Cantor Fitzgerald analyst has recently reiterated a "buy" rating on the company and has set a price target of $7.00.

Find out more about Supervalu including full access to the free equity report at:

Thermo Fisher Scientific Inc. (NYSE: TMO) shares have gained approximately 28 percent year-to-date. The company recently reported a net income $336.2 million, or $0.93 per share, for the first quarter of 2013, an increase of 21 percent from $277.3 million, or $0.75 per share, a year prior.

Find out more about Thermo Fisher Scientific including full access to the free equity report at:

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information